Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS
- 31 August 2004
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 56 (4) , 564-567
- https://doi.org/10.1002/ana.20223
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with the death of motor neurons in the spinal cord and brainstem. The cause of ALS is unknown and there is no cure. This study demonstrates, for the first time, that vascular endothelial growth factor (VEGF) delays progression of symptoms and prolongs survival in a Cu/Zn superoxide dismutase (SOD1) transgenic mouse model of ALS. These observations suggest that VEGF or related compounds, might be of value in the treatment of ALS patients. Ann Neurol 2004Keywords
This publication has 20 references indexed in Scilit:
- Neuroprotection of Ischemic Brain by Vascular Endothelial Growth Factor is Critically Dependent on Proper Dosage and May Be Compromised by AngiogenesisJournal of Cerebral Blood Flow & Metabolism, 2004
- Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factorThrombosis and Haemostasis, 2004
- The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse modelThe EMBO Journal, 2003
- VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic deathNature Genetics, 2003
- Role of Raf in Vascular Protection from Distinct Apoptotic StimuliScience, 2003
- The VIVA TrialCirculation, 2003
- From charcot to lou gehrig: deciphering selective motor neuron death in alsNature Reviews Neuroscience, 2001
- Amyotrophic Lateral SclerosisNew England Journal of Medicine, 2001
- Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse ModelScience, 2000
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993